ABSTRACT
INTRODUCTION

WHO
(1) proposed a working definition of metabolic syndrome or insulin resistance syndrome as an association of impaired glucose tolerance, diabetes mellitus and/or insulin resistance with two or more of the following components: hypertension, dyslipidemia, central obesity, and microalbuminuria. Then, the NCEP and ATP III (2) modified the WHO cut-off values and definition (required the presence of 3 of 5 of: abdominal obesity, hypertriglycedidemia, low HDL-c, hypertension, and impaired glucose tolerance based on measuring FBG). IDF (3) again proposed that abdominal obesity is diagnostic of metabolic syndrome if associated with 2 or more of ATP III criteria.
Metabolic syndrome is a cluster of metabolic abnormalities including the most dangerous risk factors for cardiovascular diseases: glucose intolerance and diabetes, abdominal obesity, high cholesterol, and arterial hypertension (4,5) . Various genetic factors in combination with specific environmental factors are believed to attribute to metabolic syndrome. Genes for β 2 -and β 3 -adrenergic receptors, lipoprotein lipase, hormone sensitive lipase, peroxisome proliferator-activated receptor-γ, insulin receptor substrate-1, and glycogen synthase are among several candidate genes involved in the metabolic syndrome (6) . Important genes that, by genetic studies, were proposed to be important factors for diabetic complications are those of renin-angiotensin system (RAS), the system that has been documented as an important regulator of blood pressure and renal homeostasis. Of these RAS genes, is the gene coding for the dipeptidyl carboxypeptidase (a zinc metallopeptidase) termed angiotensin-I-converting enzyme (ACE); or kininase II. This enzyme act to hydrolyze angiotensin-I to the potent vasopressor and aldosteronestimulating angiotensin-II, as well as to inactivate the vasodilator bradykinine (7) . The ACE gene has 26 exons and span 21kb on chromosome 17, with polymorphism consisting of either the presence (insertion; I allele) or absence (deletion; D allele) of 287 bp base pair DNA fragment within the intron 16, giving three ACE genotypes: DD genotype, II genotype, and the ID genotype (7) . As regard the ACE genotyping, it was found that the D allele is associated with higher serum ACE activity (8) ; and I/D polymorphism is associated with: diabetes (9) , hypertension (10) , coronary heart disease (11) and with diabetic nephropathy (12) . Therefore, ACE might be a candidate gene for metabolic syndrome.
So, by comparing ACE genotyping and activity among healthy subjects, type-II diabetics, and those with the cluster of the metabolic syndrome, we tried to demonstrate if there is an association between metabolic syndrome and the ACE genotyping and activity, whether the ACE polymorphism participate in the pathogenesis of various metabolic syndrome's components, and to show the distribution of ACE genotypes among the studied groups.
SUBJECTS & METHODS
One hundred subjects, with the same social and economic levels, were enrolled in this study. They were termed as the following:
Control group (Group I):
including 30, completely healthy, The ACE I/D gene polymorphism from DNA samples was determined by polymerase chain reaction (PCR) according to the method described by Lee and Tsai (15) . The primers sequences were (F:5'-CTG GAG ACC ACT CCC ATC CTT TCT-3') and (R:5'-GAT GTG GCC ATC ACA TTC GTC AGA T-3').
The reactions were transferred to the thermal cycler PTC-100 machine (MJ Research, Inc., Watertown, Mass. USA) and subjected to an initial denaturation at 94º C for 10 minutes followed by 35 cycles of (94º C for 1 minute, 60º C for 1 minute, 72º C for 1 minute) then final extension step at 72º C for 5 minutes.
After PCR, the samples were separated by 2% agarose gel electrophoresis, stained with ethidium bromide and photographed for the amplification study. 
Statistical analysis:
Statistical analysis was performed using the computer software statistical package of social science (SPSS 10.0, 1999 SPSS Inc.) ; data were expressed as mean ±SD.
Comparison between data of different groups was done using oneway ANOVA followed by multiple comparison for significance of difference (Least significant difference; LSD), whereas the non parametric values were compared by the test Chi-square. Universal correlations were performed using Pearson correlation and p value <0.05 was considered statistically significant.
To detect the likelihood of an event between 2 groups the Odds ratio was calculated by the dividing the odds in the exposed group by the odds in the control group.
RESULTS
The ACE I/D genotyping was demonstrated in figure (1 
Figure (2):
Significant correlation between plasma angiotensin converting enzyme activity and different studied parameters in the diseased and overall studied subjects
DISCUSSION
Metabolic syndrome is defined as impaired glucose regulation or diabetes mellitus and/or insulin resistance, associated with hypertension, obesity, dyslipidemia and/or albuminuria (26) . RAS, by genetic studies, has been proposed as an important genetic factor for diabetic complications and metabolic syndrome (27) . Among RAS genes, is the gene encoding for ACE, a key enzyme in the RAS system that play an important documented role in the regulation of body's internal environment. The ACE gene is characterized by insertion or deletion (I/D) polymorphism based on presence or absence of 278-bp repeat sequence within the intron 16 located on chromosome 17q23 respectively (28) . The current study revealed that ACE genotypes distribution among overall included subjects was 38%, 43% and 19 % for II, ID and DD respectively, whereas allele frequencies were 59.5 and 40.5 for I and D alleles respectively, with significant differences between these percentages. The distribution of each ACE genotype and each allele did not differed significantly between the three groups of study.
Moreover we revealed that one carrying DD genotype and D allele among the type-II diabetes group were 1.2 and 1.1 times more than subjects carrying DD genotype and D allele among control subjects respectively. As regard the metabolic syndrome it was found that the presence of DD genotype and D allele in metabolic syndrome subjects was 1.3 and 1.4 times more than in control subjects respectively; and 1.1 and 1.3 times more than in type-II diabetic subjects respectively.
These observations suggest a significant association between ACE DD genotype and both type-II diabetes mellitus and metabolic syndrome as well as suggesting D allele as a more risk factor, than I allele, for both morbidities.
The The results of present study revealed significant differences in plasma ACE activity levels between the three studied groups and also between the three genotype subgroups.
The levels were significantly higher among patient's groups compared to controls and also in patient's genotype subgroups compared to the corresponding control genotype subgroups. Also, plasma ACE activity levels were significantly higher among metabolic groups and its genotype subgroups than among type-II diabetic groups and its corresponding genotype subgroups. Furthermore, in all studied groups there was a significant increase in plasma ACE level in subjects with DD genotype (highest levels) than in subjects with ID or II genotypes; and in subjects with ID genotype (intermediate levels) than in subjects with II genotype (lowest levels).
These observations suggested that increased plasma ACE activity levels among metabolic syndrome and type-II diabetes patients is possibly the high prevalence of D-allele containing ACE genotypes. The present study's results disagree with those reported by Nagi et al.
(37) who stated that plasma ACE concentrations were not significantly different between diabetic and nondiabetic subjects.
In this study, the indices of insulin resistance and glucose metabolism were significantly higher in patient's groups and subgroups compared to the control group and corresponding subgroups, but no significant differences in these indices between metabolic group and diabetic groups and their corresponding genotype subgroups.
As regard the differences between the three ACE genotypes, it was found that, in the patient's groups, subject with DD genotype have a statistically significant increase in insulin resistance indices compared to subjects with ID and II genotypes; although no significant differences were found between the three ACE genotype subgroups in fasting blood glucose and HbA 1c among all studied groups.
Moreover, there was a significant direct correlation between plasma ACE activity (which was found to be highest among DD genotype subgroups) and FBG, HbA 1c , plasma insulin, and HOMA index in overall studied subjects. In diseased subjects plasma ACE activity was found to be directly and significantly correlated to both plasma insulin and HOMA index. In type 2 diabetics and in metabolic syndrome subjects, the contribution of increased plasma ACE activity to insulin resistance was suggested by significant direct correlation between plasma ACE level and both fasting plasma insulin and HOMA index.
The above mentioned results suggest that ACE gene DD genotype and D-allele contribute, possibly via increasing plasma ACE activity, to the pathogenesis of insulin resistance in type 2 diabetes mellitus and in metabolic syndrome (9) . The mechanism of contribution of RAS in insulin resistance could be explained by the fact that RAS and insulin signaling shared signal transduction pathways. Thus activation of RAS may inhibit metabolic action of insulin via phosphatidylinositol 3-kinase (PI3-K). found a significant increase in fasting blood glucose levels among subjects with DD polymorphism than among those with II polymorphism. Moreover, our results disagreed with those of Ryan et al.
(43) who concluded a higher plasma insulin and insulin resistance with ACE II genotype than with DD genotype in healthy overweight. Paolisso et al. (44) also reported higher insulin resistance in aged healthy Italians with II ACE genotype than in those with ID and DD genotypes. On the other hand, absence of association between insulin levels and/or insulin resistance and ACE genotyping has been reported in studies of Huang et al. (45) in control and type-II diabetic subjects.
The results of present study represent significant differences in all studied parameters of lipid profile (total cholesterol, LDL-c, HDL-c, triglycerides and APO-A) between the three groups of the study. The levels of total cholesterol, LDL-c and triglycerides were significantly higher, whereas the levels of HDL-c and APO-A were significantly lower in patient's groups compared to control group and in metabolic syndrome group compared to diabetic group. Also, when the corresponding genotype subgroups in each studied group were compared to each other the differences were the same as when the whole groups were compared. Moreover, with focusing on different ACE genotypes, the study revealed that, in the three studied groups, subjects with DD genotype have a significant increase in plasma total cholesterol, LDL-c and triglycerides levels; and a significant decrease in plasma HDL-c and APO-A levels compared to subjects with ID or II genotype.
The correlation study revealed that plasma ACE activity has a significant direct correlation with total cholesterol, LDL-c and triglycerides levels and a significant inverse correlation with HDL-c and APO-A levels among overall subjects, diseased subjects and metabolic syndrome subjects. In diabetic subjects plasma ACE was significantly and inversely correlated to HDL-c and APO-A, whereas in controls ACE directly correlated to LDL-c and indirectly to HDL-c significantly.
These results would suggest that ACE gene deletion polymorphism and increased ACE activity are obvious risk factors for dyslipidemia particularly the patterns of dyslipidemia observed in metabolic syndrome and in type-II diabetes (4) .
As regard the differences in plasma lipids between diabetics and non-diabetics, the results of Hsieh et al. (9) and Lee and Tsai (15) were in agreement with our results. They revealed significantly higher plasma total cholesterol and triglycerides in diabetics than in non diabetics. Also, studies of Frenais et al.
(46) and Dionyssiou-Asteriou et al.
reported significantly lower APO-A among diabetics than among nondiabetics. As regard differences in plasma lipids with different ACE genotypes Lee and Tsai (15) similar to our results, reported a higher prevalence of dyslipidemia and higher serum triglycerides in diabetic patients with DD genotype than in those with II genotype. Also, Oren et al. (48) stated that the mean LDL-c level was highest in DD genotype subjects and lowest in II subjects.
Controversial to our results Nagi et al.
(37) did not find an association between these lipid parameters and ACE genotyping in Pima Indians. But with respect to the effect of ACE activity on lipid profile, they revealed a significant direct correlation between the plasma ACE levels and both total cholesterol and triglycerides levels in diabetics and non-diabetics.
Our study concluded a higher incidence of microalbuminuria among metabolic syndrome patients with ACE D-allele containing genotypes than those with insertion polymorphism. By application of Odds ratio, it was found that the occurrence of microalbuminuria among DD genotype patients was 6 and 1.29 times higher than its occurrence among II and ID genotypes respectively. Also, the incidence of microalbuminuria with ID genotype was 4.66 times more than with II genotype. These results showed that ACE gene deletion may be associated with increased susceptibility to albuminuria in metabolic syndrome and in type 2 diabetic patients. Therefore, ACE gene deletion may play a role in the development and progression of nephropathy in these patients, predicting who will develop these complications.
The contribution of ACE DD genotype to this albuminuria may be attributed to our results that ACE DD genotype was associated with increased plasma ACE activity; with subsequent increase in activation of angiotensin I to angiotensin II Angiotensin II then may promote glomerular measngial and renal tubular cell growth as well as enhancement of collagen accumulation with subsequent development and progression of albuminuria (49) . Current study's results agree with those revealed by Ohno et al.
(50) who stated that, in type 2 diabetic patients, the D allele of the ACE gene was more frequent in micro-and macroalbuminuric groups than in normoalbuminuric group. As well, our results are in accordance that of Hashimoto et al. (12) who viewed an association between ACE DD genotype and proteinuria in Japanese overweight men.
There was a discrepancy between our results and those of Nakajima et al.
(51) who found that the distribution of ACE genotypes did not differed significantly between normo-, micro-, and macro-albuminuric patients, although the distribution of D allele was slightly higher in protinuric than in non-protinuric males but not females.
The results of Odds ratio revealed that the occurrence of hypertension in metabolic syndrome patients carrying DD genotype was 3.50 and 2.33 times more than its occurrence in those carrying II or ID genotypes respectively.
Thereafter, ID hypertensive subjects were 1.50 times increased than II hypertensive subjects. These results would suggest the ACE DD genotype to be associated with increased susceptibility to hypertension in metabolic syndrome patients with type-II diabetes. With the respect of obesity, the current study denies presence of association between ACE genotyping and obesity in metabolic syndrome patients.
Our results detected increased distribution of ACE II genotype among obese metabolic syndrome patients, meanwhile it was not significant. The lack of association between ACE genotypes and obesity seems to be obscure.
In close to our results Ryan et al. (43) reported an association between II genotype of ACE and obesity. Lee and Tsai (15) and Nagi et al. (37) found no differences in obesity markers (BMI and WHR) between the three ACE genotypes. Also, close to our results,
In contrast to the present study, Strazullo et al.
(57) revealed a higher prevalence of obesity in Italian males with D/D allele compared to those with I/D or I/I allele, although the differences was not statistically significant.
Genotype II which was relatively abundant in obese subjects may be responsible for production of different ACE phenotype that responsible for ACE activity in adipose tissue.
From these results we can conclude that the ACE gene, one of RAS genes, DD polymorphism was more abundant among metabolic syndrome and type-II diabetic patients; the result that provide an evidence of genetic susceptibility to the metabolic syndrome. The Deletion polymorphism of ACE gene was, moreover, associated with the components of metabolic syndrome: hypertension and microalbuminuria but not with the obesity. Also, the activity of the ACE gene enzyme was more among these patients and associated with insulin resistance as well as with atherogenic hyperlipidemia.
These 
